These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy.
    Author: Lin MT, Sun LC, Wu ET, Wang JK, Lue HC, Wu MH.
    Journal: Arch Dis Child; 2015 Jun; 100(6):542-7. PubMed ID: 25564534.
    Abstract:
    OBJECTIVE: To explore acute and late coronary outcomes and their risk/modifiers in patients with Kawasaki disease (KD). DESIGN: Retrospective study. SETTING AND PATIENTS: 1073 patients with KD identified from a tertiary care medical centre (1980-2012; 8677 patient-years). MAIN OUTCOME MEASURES: The acute coronary severities and late outcomes (survival free of coronary aneurysm persistence and ischaemia) were assessed. RESULTS: Coronary arterial lesions occurred in 40.6% of cases at their acute febrile stages, and persisted beyond 1 month in 196 (18.3%, M/F=138/58) patients: 125 (11.6%) had small aneurysms, 44 (4.1%) had medium aneurysms, and 27 (2.5%) had giant aneurysms. At follow-up (1-46 years), coronary aneurysms persisted in all with giant aneurysms, in 55% of those with medium aneurysms (18% with stenosis), and in 9% of those with small aneurysms. Ischaemia events occurred in 14 patients (M/F=13/1) and caused four deaths. Among the patients with KD with coronary aneurysms, 10-year ischaemia event-free and aneurysm persistence probability was 87.5% and 20.6%, respectively. The only independent risk for aneurysm persistence was the aneurysm severity 1 month after KD onset (χ(2)=80.73, p<10(-3)). Male patients and intravenous γ-immunoglobulin (IVIG) therapy were independent risk factors of initial coronary severity but were not associated with the late coronary outcomes, even in severity stratified subgroups. CONCLUSIONS: The coronary severity 1 month after KD onset is most crucial to the late coronary outcomes. Although IVIG use improves the initial severity of coronary lesions, it does not further modify the long-term fate of coronary aneurysms.
    [Abstract] [Full Text] [Related] [New Search]